Zymeworks Bc Inc.

Zymeworks Inc.

Nina E Weisser

Gordon Yiu Kon Ng

Grant Raymond Wickman

Mario Sanches

Eric Escobar-Cabrera

Surjit Bhimarao Dixit

Thomas Spreter Von Kreudenstein

Diana F Hausman

Harsh Pratap

Patricia Zwierzchowski

David Douda

Nicole Afacan

Patrick Kaminker

Kara White-moyes

Chayne L Piscitelli

The present disclosure relates to multivalent, e.g., trivalent, and bispecific antibody constructs capable of binding an antigen on a cytotoxic effector cell and a tumor-associated antigen (TAA) on a tumor cell. Pharmaceutical compositions comprising such antibody constructs and methods of preparing and using such constructs and compositions, e.g., for the treatment of cancer, are also disclosed.

Multivalent and bispecific antibody constructs and methods of use thereof

Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

Bispecific antigen binding constructs targeting HER2

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

Methods of using bispecific antigen-binding constructs targeting HER2

Described herein is a method of treating breast cancer comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) in combination with a CDK4/6 inhibitor to a subject.

Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer

Bispecific antigen-binding constructs targeting HER2

Bispecific antigen-binding constructs targeting Her2

Growing community of inventors

Delta, Canada

Nina E Weisser